SPECIAL REPORT
MOST SHARED
- Traveling Light in a Time of Digital Thievery
- Amid Efforts to Rescue Greece, a Lack of Trust From Allies
- How to Date a Wall Street Man
- These Problems Mean You're Doing Something Right
- Why Greece Will Default, Leave the Euro Zone
- Greece Warns Bailout Rebels of Unknown, Dangerous Path
- Italy's Mario Monti One-on-One
- In Search of America's ‘Hottest Forecasters’
- Dow vs. S&P 500: Which is a Better Investment?
- Mick Fleetwood on the MP3 ‘Dumbing Down’ of Music
- Avis on the Road to Strong Growth: Analyst
- Private Homebuilders: Dead Men Walking
- LinkedIn’s Growth Is Already Priced In: Analyst
- The Real Reason Behind Bank of America’s Rally
- 5 Hedge Funds’ Top Stocks Soar After 2011 Rout
- This Valentine’s Day Love Is Served on a Silver Platter
- Maine Caucuses a Chance to Right the Romney Ship
- Greek Debt Saga Back on Center Stage for Markets
- Greece Now Struggles to Overcome Mistrust
- Obama Budget Bets Other Concerns Will Trump the Deficit
- China President-in-Waiting to Sample Slices of America
- MF Global Trustee Sees Shortfall of $1.6 Billion
- Iran to Announce 'Very Important' Nuclear Progress
- Traveling Light in a Time of Digital Thievery
- UK Police Arrest Five at Murdoch's Sun Newspaper
RSS FEED
Pharma's Market
Text Size 
Oktoberfest For ImClone & Dendreon (Update On Mystery Bid)
UPDATE--Mystery Solved: Eli Lilly [LLY
Loading...
()
] is in advanced talks to acquire ImClone for $70 per shares according to sources. No deal is yet in place. The Lilly offer values ImClone at about at $6.1 billion.
A spokesman for BMY says, "No comment." A Spokesman for LLY says, "We don't comment on speculation that's out there in the market. We cannot confirm or deny the report."
While the Street is focused on the big vote in the Senate tonight on the bailout package, biotech investors will be on the lookout for news out of ImClone Systems.
Earlier this week the company announced that its mystery counter-bidder will decide whether to follow through on its $70-a-share offer by midnight tonight. On light volume, so far, IMCL [IMCL
Loading...
()
] is trading higher, although it's already below its best level of the morning. Bristol-Myers Squibb recently raised its offer from $60 to $62 a share, so at least a few investors seem to be making a small bet that the as-yet unidentified "large Pharma" company might start a formal bidding war.
In a research note to clients this morning Rodman & Renshaw senior biotech analyst Mike King is lowering his third-quarter sales estimates for the cancer drug Erbitux, which it shares with BMY [BMY
Loading...
()
]. But King writes, "We continue to believe that a bid in excess of $70 will likely emerge for ImClone before an acquisition is concluded. However, we would point out that Bristol has the upper hand in the negotiations." R&R makes a market in IMCL.
Meantime, this is gonna be a big month for Dendreon [DNDN
Loading...
()
]. October is when the biotech company has said it would have the interim data from the pivotal clinical trial of its prostate cancer treatment Provenge. Before you ask, DNDN has not provided any specific date or range of dates. If the mid-term study results are good enough, Dendreon officials have said the Food and Drug Administration has told them it would approve Provenge. Otherwise, patients and investors will have to wait for the final test results to come in sometime next year.
According to this week's Barron's, DNDN is 27th on the list of Nasdaq stocks with the largest short positions. However, from the end of August through the middle of September, the number of shares sold short dropped by more than 38,000. DNDN is also 17th on the list of Nasdaq stocks with the largest short interest ratios with more than 33,500,000 in bear claws as of September 15th. Remember, though, that was before the recent launch of the crackdown on short-selling.
The debate over whether the interim study results will be robust enough is intense. Oktober will be a ride on die achterbahn for Dendreon investors. Will it be the longs or the shorts who are left crying in das bier?
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes
